NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study

Novo Nordisk (NVO) has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema, in patients with obesity and type 2 diabetes (T2D) and a mean baseline body weight of 102 kg. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68 compared with placebo.NVO’s CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. T ...